These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 21368462)

  • 1. [Efficacy of chemotherapy combined with bevacizumab for metastatic colorectal cancer].
    Momoi A; Motomura S; Hashimoto C; Takasaki H; Takemura S; Takagi S; Akaike M
    Gan To Kagaku Ryoho; 2011 Jan; 38(1):79-83. PubMed ID: 21368462
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Bevacizumab in combination with mFOLFOX6 or FOLFIRI for previously treated metastatic colorectal cancer].
    Koyama M; Murata A; Kimura Y; Sakamoto Y; Morohashi H; Kimura N; Gasa F; Sato J; Terui K; Awatsu A; Hakamada K
    Gan To Kagaku Ryoho; 2010 Jun; 37(6):1069-73. PubMed ID: 20567110
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Clinical significance of bolus 5-fluorouracil for recurrent or metastatic colorectal cancer treated with FOLFOX+ BevacizumabTherapy].
    Yoshida Y; Hasegawa J; Nishimura J; Hirota M; Kim Y; Nezu R
    Gan To Kagaku Ryoho; 2011 Aug; 38(8):1293-6. PubMed ID: 21829066
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical outcomes associated with bevacizumab-containing treatment of metastatic colorectal cancer: the BRiTE observational cohort study.
    Kozloff M; Yood MU; Berlin J; Flynn PJ; Kabbinavar FF; Purdie DM; Ashby MA; Dong W; Sugrue MM; Grothey A;
    Oncologist; 2009 Sep; 14(9):862-70. PubMed ID: 19726453
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase II trial of chemotherapy plus bevacizumab as second-line therapy for patients with metastatic colorectal cancer that progressed on bevacizumab with chemotherapy: the Gunma Clinical Oncology Group (GCOG) trial 001 SILK study.
    Tsutsumi S; Ishibashi K; Uchida N; Ojima H; Hosouchi Y; Yashuda N; Kigure W; Yamauchi S; Asao T; Ishida H; Kuwano H
    Oncology; 2012; 83(3):151-7. PubMed ID: 22889925
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Feasibility of bevacizumab for elderly patients with metastatic colorectal cancer].
    Tsuchida K; Asari M; Numata K; Yoshida T; Osaragi T; Yoneyama K; Kasahara A; Yamamoto Y; Rino Y; Masuda M
    Gan To Kagaku Ryoho; 2012 Sep; 39(9):1379-83. PubMed ID: 22996773
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase II multicenter trial of bevacizumab plus fluorouracil and leucovorin in patients with advanced refractory colorectal cancer: an NCI Treatment Referral Center Trial TRC-0301.
    Chen HX; Mooney M; Boron M; Vena D; Mosby K; Grochow L; Jaffe C; Rubinstein L; Zwiebel J; Kaplan RS
    J Clin Oncol; 2006 Jul; 24(21):3354-60. PubMed ID: 16849749
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Second-line FOLFIRI plus bevacizumab for patients with metastatic colorectal cancer after resection of the primary lesion].
    Abe H; Mafune K; Minamimura K; Abe M; Umemura A; Hirata T
    Gan To Kagaku Ryoho; 2013 May; 40(5):601-4. PubMed ID: 23863581
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bevacizumab in combination with fluorouracil and leucovorin: an active regimen for first-line metastatic colorectal cancer.
    Hurwitz HI; Fehrenbacher L; Hainsworth JD; Heim W; Berlin J; Holmgren E; Hambleton J; Novotny WF; Kabbinavar F
    J Clin Oncol; 2005 May; 23(15):3502-8. PubMed ID: 15908660
    [TBL] [Abstract][Full Text] [Related]  

  • 10. FDA drug approval summary: bevacizumab (Avastin) plus Carboplatin and Paclitaxel as first-line treatment of advanced/metastatic recurrent nonsquamous non-small cell lung cancer.
    Cohen MH; Gootenberg J; Keegan P; Pazdur R
    Oncologist; 2007 Jun; 12(6):713-8. PubMed ID: 17602060
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Review: incidence and clinical significance of Bevacizumab-related non-surgical and surgical serious adverse events in metastatic colorectal cancer.
    Hompes D; Ruers T
    Eur J Surg Oncol; 2011 Sep; 37(9):737-46. PubMed ID: 21764243
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase IV study of bevacizumab in combination with infusional fluorouracil, leucovorin and irinotecan (FOLFIRI) in first-line metastatic colorectal cancer.
    Sobrero A; Ackland S; Clarke S; Perez-Carrión R; Chiara S; Gapski J; Mainwaring P; Langer B; Young S;
    Oncology; 2009; 77(2):113-9. PubMed ID: 19628950
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety of bevacizumab treatment in combination with standard chemotherapy for metastatic colorectal cancer: a retrospective review of 65 Japanese patients.
    Tamiya A; Yamazaki K; Boku N; Machida N; Kojima T; Taku K; Yasui H; Fukutomi A; Hironaka S; Onozawa Y
    Int J Clin Oncol; 2009 Dec; 14(6):513-7. PubMed ID: 19967487
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Chemotherapy with bevacizumab (BV)+modified FOLFOX6 for unresectable colorectal cancer].
    Matsumoto R; Kuroda T; Yamada H; Hasegawa K; Mamiya Y; Kon A
    Gan To Kagaku Ryoho; 2009 Nov; 36(12):2207-9. PubMed ID: 20037372
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and efficacy of FOLFIRI-bevacizumab for metastatic colorectal carcinoma as second line treatment.
    Odabas H; Ozdemir N; Isik M; Abali H; Oksuzoglu B; Kos T; Civelek B; Babacan AN; Dogan U; Zengin N
    J BUON; 2011; 16(3):460-3. PubMed ID: 22006750
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Complications of chemotherapy in combination with bevacizumab for treating metastatic colorectal cancer].
    Manikhas GM; Korolenko VO; Al'-Nekhmi AA; Antimonik NIu
    Vopr Onkol; 2010; 56(5):613-6. PubMed ID: 21137245
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bevacizumab beyond first progression is associated with prolonged overall survival in metastatic colorectal cancer: results from a large observational cohort study (BRiTE).
    Grothey A; Sugrue MM; Purdie DM; Dong W; Sargent D; Hedrick E; Kozloff M
    J Clin Oncol; 2008 Nov; 26(33):5326-34. PubMed ID: 18854571
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Evaluation of bevacizumab for advanced colorectal cancer].
    Naito M; Hoshino S; Noda N; Nakano M; Matsuo K; Yamauchi Y; Shinohara T; Tanaka S; Yamashita Y
    Gan To Kagaku Ryoho; 2010 Jan; 37(1):83-8. PubMed ID: 20087037
    [TBL] [Abstract][Full Text] [Related]  

  • 19. RIBBON-1: randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2-negative, locally recurrent or metastatic breast cancer.
    Robert NJ; Diéras V; Glaspy J; Brufsky AM; Bondarenko I; Lipatov ON; Perez EA; Yardley DA; Chan SY; Zhou X; Phan SC; O'Shaughnessy J
    J Clin Oncol; 2011 Apr; 29(10):1252-60. PubMed ID: 21383283
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Clinical impact of addition of bevacizumab to the first-line chemotherapy regimen in the treatment of patients with metastatic colorectal cancer].
    Sogabe S; Tateno T; Yagisawa M; Ishikawa M; Sawada K; Muranaka T; Umemura M; Kato R; Takasaka T; Takahashi K; Dazai M; Iwanaga I; Oda H; Miyagishima T
    Gan To Kagaku Ryoho; 2014 Sep; 41(9):1113-7. PubMed ID: 25248894
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.